High Growth Tech Stocks To Watch In Australia December 2024

As the Australian market navigates a mixed landscape with the ASX200 slightly down by 0.2% and a tight labor market reflected in an unemployment rate of 3.9%, sectors like Information Technology are showing resilience with modest gains amidst broader economic challenges. In this environment, identifying high growth tech stocks involves looking for companies that can leverage innovation and adaptability to capitalize on emerging opportunities, particularly as certain sectors like Energy and Information Technology demonstrate potential despite overall market fluctuations.

Top 10 High Growth Tech Companies In Australia

Name	Revenue Growth	Earnings Growth	Growth Rating
Infomedia	6.77%	20.97%	★★★★★☆
Clinuvel Pharmaceuticals	21.38%	26.16%	★★★★★☆
Adherium	86.80%	73.66%	★★★★★★
Pureprofile	14.31%	71.53%	★★★★★☆
Telix Pharmaceuticals	21.55%	38.32%	★★★★★★
ImExHS	20.47%	111.20%	★★★★★★
AVA Risk Group	25.54%	77.32%	★★★★★★
Pointerra	56.62%	126.45%	★★★★★★
Wrkr	37.21%	98.46%	★★★★★★
SiteMinder	18.83%	60.52%	★★★★★☆

Click here to see the full list of 58 stocks from our ASX High Growth Tech and AI Stocks screener.

We're going to check out a few of the best picks from our screener tool.

Nuix (ASX:NXL)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Nuix Limited offers investigative analytics and intelligence software solutions across various global regions, with a market capitalization of A$2.10 billion.

Operations: The company generates revenue primarily from its Software & Programming segment, which reported A$220.62 million.

Nuix has shown a promising trajectory, with its revenue expected to grow by 15.2% annually, outpacing the Australian market's average of 5.8%. This growth is underpinned by significant advancements in earnings, projected at an impressive rate of 40.2% per year, which starkly contrasts with the broader market's expectation of 12.5%. Despite facing challenges such as a one-off loss of A$6.4M last financial year and shareholder dilution, Nuix was recently added to the S&P/ASX 300 and Small Ordinaries Indexes, signaling increased investor recognition and trust in its market position. These developments suggest that while there are hurdles, Nuix is navigating its path forward with strategic agility in the competitive tech landscape.

• Delve into the full analysis health report here for a deeper understanding of Nuix.

• Assess Nuix's past performance with our detailed historical performance reports.

Opthea (ASX:OPT)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Opthea Limited is a clinical-stage biopharmaceutical company focused on developing and commercializing drugs for eye diseases in Australia and the United States, with a market cap of A$824.83 million.

Operations: Opthea Limited generates revenue primarily from its Medical Technology and Healthcare segment, amounting to $0.26 million. The company is focused on the development and commercialization of eye disease treatments in key markets such as Australia and the United States.

Opthea's trajectory in the high-growth tech sector is marked by an aggressive R&D strategy, with a significant 51.7% annual revenue growth forecast, outstripping the Australian market's average of 5.8%. The company is steering towards profitability with anticipated earnings growth of 61.9% per year, reflecting its deep commitment to innovation in ophthalmic treatments. Recent executive appointments and global conference presentations underscore Opthea’s strategic focus on expanding its influence and expertise in the biotech field, particularly within wet AMD therapies through upcoming Phase 3 trial results for sozinibercept. These developments signal Opthea's potential to reshape treatment paradigms and enhance shareholder value as it progresses towards key clinical milestones.

• Navigate through the intricacies of Opthea with our comprehensive health report here.

• Learn about Opthea's historical performance.

Xero (ASX:XRO)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Xero Limited is a software as a service company that offers online business solutions for small businesses and their advisors across Australia, New Zealand, and internationally, with a market cap of A$25.76 billion.

Operations: Xero generates revenue primarily through providing online solutions for small businesses and their advisors, amounting to NZ$1.91 billion.

Xero's recent financial performance underscores its robust position in the tech landscape, with a notable increase in half-year revenue to NZD 995.87 million from NZD 799.55 million and a surge in net income to NZD 95.09 million from NZD 54.08 million previously. This growth is complemented by a promising forecast of earnings growing at an annual rate of 26.4%, significantly outpacing the broader Australian market's average of 12.5%. The company also demonstrates strong innovation commitment, evidenced by R&D expenses aligned with strategic goals to enhance cloud-based accounting solutions, ensuring it remains competitive in a rapidly evolving digital economy. As Xero continues to expand its technological capabilities and market reach, these factors collectively signal potential for sustained growth despite leadership transitions marked by the CFO’s upcoming departure.

• Dive into the specifics of Xero here with our thorough health report.

• Review our historical performance report to gain insights into Xero's's past performance.

Taking Advantage

• Get an in-depth perspective on all 58 ASX High Growth Tech and AI Stocks by using our screener here.
• Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
• Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.

Ready For A Different Approach?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com